NCT01780662 · OUTCOME

Plasma Level of Thymus and Activation-Regulated Chemokine (TARC)

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma · Source last updated 2021-10-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: pg/ml
Interval / dispersion: Full Range
Time frame: From baseline to time prior to cycle 2

What was measured

Limit to 41 evaluable patients who received dose 1.8 mg/kg

Analysis population: 4 eligible patients did not consent for genetic studies. 3 of the 41 did not have baseline TARC and 6 did not have TARC prior to cycle 2.

Groups in this outcome

Dose 1.8mg/kg

Evaluable patients who received dose 1.8mg/kg.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Dose 1.8mg/kg	41

Reported measurements

Baseline

Analysis denominator · Participants

Group	Source count
Dose 1.8mg/kg	38

Values in pg/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Dose 1.8mg/kg	5700	Not reported	389	18,667	Not reported

Prior to Cycle 2

Analysis denominator · Participants

Group	Source count
Dose 1.8mg/kg	35

Values in pg/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Dose 1.8mg/kg	668	Not reported	6	9,718	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
389
upper Limit
18,667
value
5700
denoms
counts
group Id
OG000
value
38
units
Participants
title
Baseline
categories
measurements
group Id
OG000
lower Limit
6
upper Limit
9,718
value
668
denoms
counts
group Id
OG000
value
35
units
Participants
title
Prior to Cycle 2

denoms

counts
group Id
OG000
value
41
units
Participants

description

Limit to 41 evaluable patients who received dose 1.8 mg/kg

dispersion Type

Full Range

groups

description
Evaluable patients who received dose 1.8mg/kg.
id
OG000
title
Dose 1.8mg/kg

param Type

MEDIAN

population Description

4 eligible patients did not consent for genetic studies. 3 of the 41 did not have baseline TARC and 6 did not have TARC prior to cycle 2.

reporting Status

POSTED

time Frame

From baseline to time prior to cycle 2

title

Plasma Level of Thymus and Activation-Regulated Chemokine (TARC)

type

SECONDARY

unit Of Measure

pg/ml

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice